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Abstract
Background: Fosfomycin is a cell wall inhibitor used efficiently to treat uncomplicated urinary tract and gastrointestinal
infections. A very convenient feature of fosfomycin, among others, is that although the expected frequency of resistant
mutants is high, the biological cost associated with mutation impedes an effective growth rate, and bacteria cannot offset
the obstacles posed by host defenses or compete with sensitive bacteria. Due to the current scarcity of new antibiotics,
fosfomycin has been proposed as an alternative treatment for other infections caused by a wide variety of bacteria,
particularly Pseudomonas aeruginosa. However, whether fosfomycin resistance in P. aeruginosa provides a fitness cost still
remains unknown.
Principal Findings: We herein present experimental evidence to show that fosfomycin resistance cannot only emerge easily
during treatment, but that it is also cost-free for P. aeruginosa. We also tested if, as has been reported for other species such
as Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis, fosfomycin resistant strains are somewhat compromised in
their virulence. As concerns colonization, persistence, lung damage, and lethality, we found no differences between the
fosfomycin resistant mutant and its sensitive parental strain. The probability of acquisition in vitro of resistance to the
combination of fosfomycin with other antibiotics (tobramycin and imipenem) has also been studied. While the combination
of fosfomycin with tobramycin makes improbable the emergence of resistance to both antibiotics when administered
together, the combination of fosfomycin plus imipenem does not avoid the appearance of mutants resistant to both
antibiotics.
Conclusions: We have reached the conclusion that the use of fosfomycin for P. aeruginosa infections, even in combined
therapy, might not be as promising as expected. This study should encourage the scientific community to assess the in vivo
cost of resistance for specific antibiotic-bacterial species combinations, and therefore avoid reaching universal conclusions
from single model organisms.
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Introduction
Amongst a number of old antibiotics being used once more as
appealing alternatives for the treatment of different infections,
fosfomycin (Fos) displays some features that place it as a very
promising compound [1]. Although its use has traditionally been
focused on urinary tract infection pathogens, fosfomycin is a
broad-spectrum bactericidal antibiotic, that is active against both
gram-positive and gram-negative bacteria [2]. It has shown almost
no toxicity and allergenicity in humans [3]. It displays little cross-
resistance with other antibiotics, probably because it is chemically
unrelated to any other known antimicrobial agent [2,3]. Also,
several studies have pointed out the synergistic effect of fosfomycin
when used in combination with other antimicrobials [4,5,6,7].
Fosfomycin treatments have shown a relatively low proneness of
resistant mutants to persist in vivo, leading to a good effectiveness in
the therapy, at least against Escherichia coli [8]. However, recently
the acquisition of fosfomycin resistance in a previously circulating
CTX-M-15-producing E. coli O25b-ST131-phylogroup B2 strain
has been reported. This apparently occurred when the use of
fosfomycin was increased by 50% [9].
The emergence of antibiotic resistance in a bacterial population
is shaped by several factors, of which the mutation rate to
resistance and the fitness cost of the mutants have been considered
critical [10]. If resistance implies a considerable cost for the
bacteria, their growth rate would not be enough to offset the wash
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mediated by the immune system, or it might allow the more fit
susceptible bacteria to out-compete the resistant ones once the
antibiotic is removed [10].
The trend of resistant bacteria to have a competitive
disadvantage in a untreated environment is related to the precise
mechanism of the resistance in question. Numerous types of
resistance achieved by chromosomal mutations are caused by
target alterations [11]. In these cases a consistent fitness cost may
appear if the resistant target displays a somewhat suboptimal
functionality, as has been shown, for example, with some
mutations in the gene rpsL conferring streptomycin in bacteria
such as E. coli or Salmonella spp. [12]. Another prominent way to
attain resistance is determined by accessory elements, where
resistance is afforded by enzymes or pumps that inactivate or
remove the antimicrobial from the cell [13]. This type of resistance
may also give rise to fitness cost, as the replication and activity
of the elements themselves could involve some metabolic
expenditures [11].
In the specific case of fosfomycin, resistance is mainly acquired
by reducing the cell uptake of the drug [14,15,16]. This kind of
resistance has been widely shown to compromise E. coli at a slower
rate of growth when compared to that of the sensitive parental
strains [8,17,18], probably because most mutations disturb carbon
metabolism [8]. In addition, and very conveniently for humans,
these mutants also displayed a reduced virulence represented by
lower adhesion to epithelial cells [18,19,20]. The data for other
species are scarce, but it has been reported that Klebsiella
pneumoniae and Proteus mirabilis, common bacteria also causing
uncomplicated urinary tract infections, follow the same trend as
E. coli [18]. Surprisingly, a new resistance mechanism based on
amino acid substitutions in MurA, the target protein of
fosfomycin, has recently been reported. Unfortunately, the
authors have not estimated the cost associated to such a
modification [21].
Recently it has been reported that the use of fosfomycin be
extended in order to treat pathogens like Pseudomonas aeruginosa [2],
where the emergence of antibiotic resistance has led to a
unpleasant scarcity of treatments [22]. P. aeruginosa is one of the
leading nosocomial pathogens worldwide. The most severe
infections produced by P. aeruginosa occur in Intensive Care
Unit patients, those suffering from chronic respiratory diseases
and immunocompromised individuals [23]. Considering the
example of E. coli, it seems reasonable to expect that fosfomycin
might serve as a genuine alternative to treat infections caused
by multidrug resistant P. aeruginosa. This possibility has been
substantiated by published data showing that fosfomycin,
furthermore, could reveal a particular effectiveness when used
in combined therapy with other well-known antipseudomonal
agents [2,4,5,6,7].
In a previous work, we reported that P. aeruginosa has a high
mutation frequency to fosfomycin resistance in vitro [24]. These
observations in vitro could undermine the good expectations
created about fosfomycin. However, sometimes the data gener-
ated in vitro do not agree with the results attained in vivo [10,25].
Here, we undertook the assessment of this disturbing possibility,
monitoring the emergence of fosfomycin resistant (Fos-R)
mutants in an in vivo murine model. We then checked the fitness
cost caused by the inactivation of glpT in one insertion (null)
mutant, as well as its virulence relative to the sensitive parental
strain. Our results indicate a deviation from the E. coli model,
disproving any connection between fosfomycin resistance, fitness
cost or loss of any trait conferring bacterial virulence in P.
aeruginosa.
Methods
Ethics Statement
All animal experiments were approved by the animal ethics
committee of the University of the Balearic Islands, Spain. All
animals were handled and housed in strict accordance with
guidelines from the University of the Balearic Islands.
Bacteria and media
The P. aeruginosa PA14 and its derivative mutants mutS::
MAR2xT7 and glpT::MAR2xT7 were kindly provided by Dr. N.
T. Liberati [26]. All the P. aeruginosa strains were cultured in Luria-
Bertani (LB) or Mueller-Hilton at 37uC, and gentamycin (10 mg/
ml) was added when appropriate. For the biofilm assay, LB and
FBA minimal media were used [27].
P. aeruginosa lung infection mouse model
The murine model of P. aeruginosa lung infection was established
by intranasal inoculation of bacteria [28,29,30]. Briefly, for the
preparation of the inocula, bacteria (P. aeruginosa strains PA14,
PA14mutS::MAR2xT7, PA14glpT::MAR2xT7 or a 1:1 mix of
PA14/PA14glpT::MAR2xT7) were grown in LB to 0.5 OD
600 nm, centrifuged at 10,000 g for two minutes and diluted 10-
fold in saline solution (1 and 5-fold dilutions in saline solution were
also tested during the standardization of the model). Finally, serial
1/10 dilutions of bacterial suspensions were plated in MHA to
estimate bacterial viability counts.
Female C57BL/6J mice were used. All animals weighed 20 to
25 g and were provided by Harlan Ibe ´rica, S. L. The animals were
specific pathogen free and nourished ad libitum with sterile water
and food. Before inoculation, the mice were anesthetized by
intraperitoneal injection of ketamine and xylazine (100 mg and
10 mg per kg of body weight respectively). Forty microliters of the
corresponding bacterial suspension, containing the indicated
bacterial counts, were inoculated intranasally by pippeting directly
in nasal orifices.
In addition to the evaluation of associated mortality and lung
bacterial load, lung histopathology studies were performed.
Briefly, lungs were fixed in 10% formalin, embedded in paraffin,
sectioned (4 to 6 mm), and stained with hematoxylin and eosin.
Lung inflammation was then blindly scored by an expert
pathologist using the criteria of Johansen et al. [31] (1, normal;
2, mild focal inflammation; 3, moderate to severe focal
inflammation with areas of normal tissue; 4, severe inflammation
to necrosis and severe inflammation throughout the lung).
Pulmonary infection survival model
Three groups of 10 mice each per strain were inoculated with
two different bacterial inocula of 1610
6 and 5610
5 of bacteria per
animal of strains PA14 and PA14glpT::MAR2xT7 approximately,
and mortality was recorded for 7 days. A Kaplan-Meier test was
performed to determine the difference between mortality curves in
the survival experiments. P values less than 0.05 were considered
to be statistically significant.
Estimation of spontaneous Fos-R mutation rates
For an estimation of the in vitro spontaneous mutation rate of
PA14 and its derivative mutant mutS::MAR2xT7 strains, approx-
imately 10
3 cells from overnight cultures were inoculated in 8
tubes, each containing 1 ml of LB, and subsequently incubated at
37uC with strong shaking for 16 h. Aliquots from successive
dilutions or concentrated cultures were plated onto Mueller-
Hinton agar (MHA) plates with fosfomycin (128 mg/ml). Addi-
tionally, appropriate dilutions with no antibiotic were plated onto
Fosfomycin Fitness Cost
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24 h of incubation were determined. The mutation rate was then
estimated using the Jones median estimator [32], and 95%
confidence intervals were calculated using JONATOR (v0.1), a
software developed in gfortran which implements an algorithm
described elsewhere [33]. This software is free and available upon
request. The same procedure was followed for an estimation of the
mutation rate in vivo, but in this case, 8 mice were inoculated
intranasally with approximately 5610
5 bacteria per animal from
log-phase cultures of PA14 and the mutS-deficient strain. Lung
homogenates were then obtained 48 hours postinfection, as
described elsewhere. Proper dilutions of the lung homogenate
were plated, as described for the procedure in vitro.
Estimation of the frequencies of spontaneous mutants
resistant to fosfomycin, tobramycin and imipenem
An estimation of the frequencies of spontaneous mutants
resistant to fosfomycin (128 mg/ml), tobramycin (4 mg/ml),
imipenem (4 mg/ml) and the combinations of tobramycin plus
fosfomycin (4 and 128 mg/ml, respectively) and imipenem plus
fosfomycin (4 and 128 mg/ml, respectively) was performed for the
PA14 and mutS::MAR2xT strains, as previously described [24]. In
the case of the glpT::MAR2xT strain, the mutant frequency was
determined for tobramycin (4 mg/ml) and imipenem (4 mg/ml) to
study the possible epistatic effects of resistance to fosfomycin and
these two antibiotics.
Evaluation of the fitness and in vivo selection of
fosfomycin resistant mutants
Mice were inoculated with approximately 5610
5 cells of strains
PA14, PA14mutS::MAR2xT7 and PA14glpT::MAR2xT7 in saline
solution. Twenty-four hours after inoculation, two groups of 8
mice per strain were either treated with fosfomycin by receiving
two intraperitoneal injections in saline solution with an interval of
8 hours (200 mg/kg/8 h) [34,35,36] or untreated. After 48 hours
of inoculation (16 h after the end of the treatment in the case of
fosfomycin-treated mice), the animals were sacrificed and their
lungs aseptically extracted. The left lung was homogenized in 2 ml
of saline using the Ultra-Turrax T-25 disperser (IKA, Staufen,
Germany). Serial 1/10 dilutions were plated in MHA, and the
total bacterial load was determined. To quantify Fos-R mutants,
lung homogenates or serial 1/10 dilutions were placed in MHA
plates containing Fos 128 mg/ml. The established lower limit of
detection was 4 cfu of mutants per lung. The statistical differences
among groups were estimated by a Kruskal-Wallis test for lung
bacterial counts, and the Mann-Whitney U test was used to
compare the proportion of Fos-R mutants between the group
receiving fosfomycin and the untreated one. P values of less than
0.05 were considered to be statistically significant.
Competition experiments
Sixteen mice were inoculated with a 1:1 mix of PA14 and
PA14glpT::MAR2xT7 for a final inoculum size approximately of
5610
5. Twenty-four hours after inoculation, the mice were
divided into two groups (8 mice each) and treated with Fos
(200 mg/Kg/8 h) or untreated. After 48 hours of inoculation
(16 h after the end of the treatment in the case of Fos-treated
mice), the animals were sacrificed and their lungs aseptically
extracted. The left lung was homogenized in 2 ml of saline using
the Ultra-Turrax T-25 disperser (IKA, Staufen, Germany). Serial
1/10 dilutions were plated onto MHA and MHA with 10 mg/ml
of gentamycin to determine the total bacterial load and the
PA14glpT::MAR2xT7 bacterial load, respectively. In a similar way,
eight tubes were inoculated with approximately 10
3 bacteria of
each bacterial strain in 5 ml of LB and incubated at 37uC with
agitation for 24 h. The bacterial counts were determined following
the procedure described above for lung homogenate. The
competition index (CI) was defined as the glpT::MAR2xT7
mutant/wild-type ratio. The statistical analysis of the the CI
values distribution was performed by a Mann-Whitney U test. P
values of less than 0.05 were considered to be statistically
significant.
Analysis of Fos-R mutants generated in vivo
For the complementation studies 10 Fos-R mutants isolated
from 10 different non-treated mouse lungs inoculated with the
wild type strain, were complemented with the plasmid pBBR-glpT,
as previously described [37]. The plasmid pBBR-glpT and its
parental empty vector pBBR1MCS-3 [38] were introduced by
electroporation into all the isolated Fos-R mutants. Transformants
were selected on LB-agar supplemented with 150 mg/ml of
tetracycline. The minimal inhibitory concentration (MIC) of
fosfomycin was determined as described [39] for three colonies
of every transformed mutant. The glpT gene of all mutants was
sequenced, and compared with the wild type gene as described
[37].
Biofilms
An abiotic solid surface biofilm formation assay was performed
in 96-well polystyrene microtiter plates in LB and minimal FBA
[27] media in a humid chamber at 37uC, as described previously
[40]. Biofilms were quantified after seven days of incubation. Forty
independent replicas were carried out for each strain. Data were
compared by a Student’s t-test.
Antibiotic susceptibility testing
Minimal inhibitory concentrations (MICs) of fosfomycin,
tobramycin and imipenem were determined for the PA14 strain
and its derivative mutants mutS::MAR2xT7 and glpT::MAR2xT7 by
the broth microdilution method, as recommended by the CLSI
[39].
Results
glpT null mutant is as lethal as its parental strain
We did not detect any statistically significant difference in
mortality between the PA14 wild type strain and the null mutant
glpT::MAR2xT7 (Fos-R), independently of the size of the inoculum
(Figure 1). The Kaplan-Meier analysis revealed no discrepancy in
the mortality curves between strains receiving the same inoculum
(p=0.81, p=0.21, for approximately 1610
6 and 5610
5 bacteria,
respectively). These results indicate that the disruption of the glpT
gene does not interfere with the infective capacity and mortality
caused by P. aeruginosa in this model.
Effect of fosfomycin treatment in bacterial load of the
wild type, Fos-R, and mutS strains
The colonization of mice lungs by P. aeruginosa PA14 (median
9.16610
7, interquartile range from 1.57610
7 to 1.73610
8) forty
eight hours post infection did not show statistical differences in the
number of colony-forming units (cfu) per mouse, in comparison
with the other two strains, mutS::MAR2xT7 (median 8.86610
7,
interquartile range from 2.15610
7 to 2.55610
8) and
glpT::MAR2xT (median 2.95610
7, interquartile range from
1.12610
7 to 1.30610
8) (p=0.44). On the other hand, when mice
were treated with fosfomycin, bacterial counts of the wild type
Fosfomycin Fitness Cost
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5, interquartile range from 2.65610
5 to
1.66610
6) and the mutS-deficient mutant (median 6.60610
5,
interquartile range from 1.18610
5 to 2.06610
6) were dramatically
decreased by two orders of magnitude (p=0.005 and p=0.009,
respectively). However, the glpT::MAR2xT mutant did not suffer
any drop in bacterial counts (median 4.19610
7, interquartile
range from 2.01610
7 to 1.06610
8) with no differences with the
non-treated experiment (p=0.91) (Figure 2A).
The proportion of resistant mutants is greatly increased in the
wild type strain after fosfomycin treatment (Figure 2B), especially if
we consider that this increase appeared only after 24 hours from
the time the antibiotic was administered. The untreated group has
the expected proportion of Fos-R mutants according to its
mutation frequency (median 1.58610
26, interquartile range from
3.62610
27 to 5.69610
26). However, the proportion of wild type
Fos-R cells increased by two orders of magnitude (median
9.82610
25, interquartile range from 1.56610
25 to 5.76610
24),
which represents a more than 60 fold increase and is statistically
significant (p=0.009) (Table 1). Furthermore, for the PA14
mutS::MAR2xT7 strain this phenomenon was agravated. While
the proportion of resistant mutants in untreated mice was as
expected (median 2.54610
24, interquartile range from 8.27610
25
to 7.71610
24), in treated mice the proportion increased up to two
fosfomycin resistant mutants for every ten bacteria (median
1.70610
21, interquartile range from 2.71610
22 to 7.15610
21),
which corresponds to a greater than 600 fold increase and is
statistically significant (p=0.001) (Table 1).
One interesting point is that the median of the absolute
number of mutants actually remains constant if we compare the
Fos-R mutant load in mice receiving fosfomycin or not, although
the total bacterial count decreased by two orders of magnitude in
the dosed mice. This indicates that from the start of fosfomycin
dosing, probably because the bacterial load was very high at that
point, there is a multiplicity problem that limits the amount
of mutants. However, when mice are dosed, the number of
fosfomycin-susceptible bacteria diminish, thus the resistant ones
can prevail at a higher rate in comparison with the non-treated
group.
Figure 1. Mortality curves. Mice were infected with two different inocula of P. aeruginosa PA14 (blue lines) and its mutant glpT::MAR2xT7
derivative (red lines) strains. The Kaplan-Meier analysis failed to detect any significant difference between curves from the same bacterial inoculum
(1610
6 cell (crosses) and 5610
5 cells (diamonds)) (p=0.81 and p=0.21, respectively).
doi:10.1371/journal.pone.0010193.g001
Figure 2. Recovery of bacteria from lungs 48 hours post
infection. Mice were infected with approximately 5610
5 cfu/animal
and treated with two doses of fosfomycin (200 mg/kg) 24 hours after
inoculation or with no antibiotic. PA14 (blue columns) and its mutant
derivatives mutS::MAR2xT7 (red columns) and glpT::MAR2xT7 (gray
columns) (A). Ratio of Fos-R mutants/total bacteria in lungs from
treated and non-treated mice (B). Values are medians and error bars
represent interquartile ranges.
doi:10.1371/journal.pone.0010193.g002
Fosfomycin Fitness Cost
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to those in vitro
Results shown in figure 3 indicate that the mutation rates
obtained in vitro and in vivo are very similar (95% confidence
interval). As expected, mutation rates to fosfomycin resistance are
in agreement with the previously described values for these P.
aeruginosa strains [24]. The values were around 10
25 for the mutS-
deficient mutant, while the parental strain showed values two
orders of magnitude lower for both the in vitro and the in vivo
experiments. The high dispersion in the data corresponding to the
in vivo experiment is notable and probably due to the innate
variation of the animal models compared to the controlled
laboratory conditions of the in vitro experiments. These results
indicate that there is no limitation in the emergence of in vivo Fos-
R mutants in P. aeruginosa.
Wild type strain did not outcompete the Fos-R mutant in
vivo or in vitro
The in vitro competition experiment rendered no statistical
differences between the WT strain and glpT mutant (CI=1.04;
p=0.80). Similarly, in the in vivo competition experiment in mice
which did not receive fosfomycin treatment, the competition index
between the wild type strain and glpT-deficient mutant, was 0.78,
indicating no fitness advantage in any strain (p=0.22). As
expected, the scenario changed totally when the mice were treated
with fosfomycin. In this case the CI rose to 9.70 in favour of the
Fos-R mutant (p=0.02), showing that Fos-R mutants will prevail
in the population when pressure is exerted by fosfomycin.
All Fos-R mutants generated in vivo contain mutations in
the glpT gene
Complementation studies showed that glpT mutations were the
cause of fosfomycin resistance in vivo in all cases. Ten randomly
chosen mutants from the wild type strain recovered fosfomycin
sensitivity upon complementation with the glpT wild type gene.
These results coincide with those from our previous work [37].
The sequence analysis revealed different mutations in the glpT
gene (Table 2). The mutations consisted mainly of single-base
deletions (5 mutants), which caused inactivation of the gene by
frameshifts. There were also deletions of 2, 6 and 12 pb causing
frameshifts or loss of 3 or 4 aminoacids respectively. Additionally,
a G to A transition was detected at position 900 of the ORF.
Inactivation of glpT does not affect biofilm formation in
vitro
We could not detect any statistically significant difference
between the wild type strain and its glpT::MAR2xT derivative in
biofilm formation. Figure 4 shows the ability of the two strains to
form biofilm in FBA (mean 6 standard deviation: 0.1960.07 for
the wild type and 0.1760.05 for the glpT-deficient mutant,
p=0.31) or LB (mean 6 standard deviation: 0.3960.12 for the
wild type and 0.4160.13 for the glpT-deficient mutant, p=0.59).
Histopathology studies
Inflammation was scored in 10 mice per strain by using the
criteria of Johansen et al. [31]. In summary, both strains (PA14
and PA14glpT::MAR2xT7) induced a very high level of inflamma-
tion (3.960.32 and 3.660.97; mean and standard deviation of
scores for PA14 and PA14glpT::MAR2xT7, respectively) with no
significant differences between them (p=0.40). Most of the
infected mice (90% and 80% for PA14 and PA14glpT::MAR2xT7,
respectively) had a score of 4 (from severe inflammation to necrosis
and severe inflammation throughout the lung) (Figure 5).
Frequency of emergence of resistant mutants to
combined antibiotics
To investigate the possibility of appearance of double mutants
with resistance to the combinations of fosfomycin with different
antibiotics, we first determined the MICs of these antibiotics for
the PA14 strain and its derivatives mutS::MAR2xT7 and
glpT::MAR2xT7 (Table 3). The mutant frequencies of resistance
to the combinations of tobramycin plus fosfomycin (4 and 128 mg/
ml, respectively) and imipenem plus fosfomycin (4 and 128 mg/ml,
respectively) were studied. Obviously, the frequencies of mutants
resistant to the single antibiotics fosfomycin (128 mg/ml), tobra-
mycin (4 mg/ml) and imipenem (4 mg/ml) were also calculated.
Table 4 shows that the frequency of mutants resistant to the
combination of fosfomycin with tobramycin is below our limit of
detection (#10
211), making improbable the emergence of
resistance to both antibiotics when administered together, even
in a hypermutable background. However, the frequency of
mutants resistant to the combination of imipenem plus fosfomycin
is relatively high in the wild type (2.1610
29) with a 2-log increase
in the hypermutator mutant (1.1610
27). These results suggest that
Table 1. Amplification of fosfomycin resistant mutants in
mice treated with the antibiotic.
Strains
FosR mutant/total
cfu (treated mice)
FosR mutant/total
cfu (untreated mice)
Fold increase
in Fos-R
PA14 WT 9.8610
5 1.58610
6 61.98
mutS::MAR2xT7 1.70610
1 2.54610
4 666.76
Fold increase values were calculated as the ratio between the median of the
proportion of Fos-R mutants/total bacterial counts (figure 2B) of treated and
untreated mice.
doi:10.1371/journal.pone.0010193.t001
Figure 3. Mutation rates. in vivo (acute mice lung infection model,
red columns) and in vitro (blue columns) of P. aeruginosa PA14 and its
mutant derivative mutS::MAR2xT7 strains are shown. Bars represent
confidence intervals at a signification level of 0.05.
doi:10.1371/journal.pone.0010193.g003
Fosfomycin Fitness Cost
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fosfomycin with some antibiotics may not be very difficult for P.
aeruginosa. Interestingly, the frequencies of mutants resistant to
either tobramycin or imipenem of the glpT-deficient strain were
similar to those of the wild type. Thus, there is apparently no
epistatic effect between the resistance determinants of the pairs
tobramycin/fosfomycin and imipenem/fosfomycin.
Discussion
Among the different factors contributing to the ascent of
antibiotic resistance, fitness cost is now recognized as prominent
and one that ought to be evaluated when assessing the suitability of
any drug treatment [8,10]. Here we have shown that in the
absence of fosfomycin, the P. aeruginosa PA14 wild type strain
(sensitive) was unable to outcompete the null glpT mutant (Fos-R
strain) after two days of in vivo or 24 hours of in vitro competition.
Similar results were obtained previously in an in vitro experiment
comparing growth rate in minimal media [37].
On the other hand, after two days of acute lung infection, the
bacterial lung counts and the ability of the glpT mutant to cause
death did not differ from the parental strain. These results clearly
indicate that fosfomycin resistance does not exert a significant
burden on fitness or virulence for P. aeruginosa.
This divergence from the E. coli patterns could be explained to
some extent by the fact that, although both species share the
reduction in uptake of fosfomycin on the basis of resistance
mechanism [8,14,15,16,37], they apparently differ in the specific
target genes for mutation and their metabolic implications. It is
well established that, in E. coli and other gram negative species
fosfomycin access primarily through the L-alpha-glycerol-3-
phosphate transport system (glpT), and to a lesser extent via the
hexose phosphate transport system (uhpT) [15]. Moreover, these
two genes are known to be positively regulated by cAMP, and so
mutations that lower the cAMP level in the cell (i.e. in the cyaA and
ptsI genes) can induce resistance as well [41]. This reduction in
cAMP levels can produce profound alterations to the bacterial
metabolism, and can probably explain the significant reduction in
fitness and virulence shown for many resistant isolates in E. coli [8].
Aldoght, Fos-R clinical isolates of E. coli are now being found and
suggesting that this is a viable threat [9,21].
In contrast, the uptake of fosfomycin in P. aeruginosa depends
exclusively on GlpT permease [37], which does not seem to be
regulated by cAMP levels. Indeed, the glpT gene is isolated in the
P. aeruginosa genome (www.pseudomonas.com), while the E. coli
ortholog is included inside the well-known glg operon [42]. This
may be related to another radical difference between these two
species, as has been stated in the case of P. aeruginosa which displays
a higher preference for glycerol as carbon source than for glycerol-
3-phosphate [43]. These observations could be understood
considering the different ecology of both species.
We have also performed an analysis of the glpT sequences from
Fos-R mutants obtained in vivo and complementation studies,
which show that fosfomycin resistance is acquired in P. aeruginosa
by any mutation capable of inactivating GlpT activity. From a
comparative point of view with in vitro generated mutants,
mutational pathways appear to be very similar in both conditions.
Table 2. Mutations in glpT of ten randomly chosen spontaneous mutants of P. aeruginosa PA14 selected from in vitro and in vivo
experiments.
Inactivating mutations of glpT in vitro and in vivo
in vitro [37] in vivo (this work)
Mutant No. Mutation position Mutant No. Mutation position
FosR-7 A59 deletion, 1 bp (frameshift) FosR-5 T215CGCCA220 deletion 6 bp
FosR-9 C219ATCGC225 deletion, 6 bp FosR-6 T221CGCCT227 deletion 6 bp
FosR-1 A220TCGCC226 deletion 6 bp FosR-4 T226A227 deletion, 2 bp (frameshift)
FosR-2 T365CATGTT371 deletion, 7 bp (frameshift) FosR-9 T377 deletion, 1 bp (frameshift)
FosR-3 G410 to A transition FosR-10 G619 deletion, 1 bp (frameshift)
FosR-5 G596 deletion, 1 bp (frameshift) FosR-3 A869 deletion, 1 bp (frameshift)
FosR-10 C975GG insertion, 3 bp FosR-2 T887 deletion, 1 bp (frameshift)
FosR-4 A1006 to C transition FosR-7 G900 to A transition
FosR-8 C1086 to G transition FosR-8 C1032GGCAACCCGGC1043 deletion 12 bp
FosR-6 G1098 to A transition FosR-10 T1231 deletion, 1 bp (frameshift)
Mutants were arranged according to the nucleotide position using the A of the ATG of the ORF as reference.
doi:10.1371/journal.pone.0010193.t002
Figure 4. Seven-day biofilm formation. Biofilm formation of P.
aeruginosa PA14 (red columns) and its mutant derivative glpT::MAR2xT7
(gray columns) is shown. The values are represented as the mean 6 SD.
Forty replicas were performed per strain and medium. No statistically
significant differences were detected between strains for each medium
(FBA, p=0.31; LB, p=0.59).
doi:10.1371/journal.pone.0010193.g004
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medical stand point. First, our data demonstrate that the fitness
cost of antibiotic resistance needs to be measured for each
particular species of interest, and that the observations made in
just one species cannot be extrapolated to another, since the
genetic particularities might modulate the effects of bacterial
fitness. Moreover, fosfomycin resistant clinical isolates of E. coli are
now being found, suggesting that this is a viable threat [9,21].
Second, our results curb the good prospects that fosfomycin has
recently promised, at least for its use on P. aeruginosa infections.
Similarly, it has been reported that there is no repercussion for
fitness in any other resistance mechanism mediated by gene
inactivation in P. aeruginosa. A partial deregulation of ampC
expression by mutation of its repressor ampD confers efficient
resistance to cephalosporins, without biological cost, due to two
other copies of ampD [44]. However, contrarily to what occurs
with glpT mutations, where a very high level of resistance is
conferred, the ampD-based resistance is far from being complete.
The high proportion of fosfomycin mutants generated by the
hypermutable mutS-deficient strain indicates a real danger of rapid
emergence of resistant mutants during a treatment. This is
especially true in chronic respiratory infections, where one of the
most prevalent and dangerous bacterial pathogens is P. aeruginosa
[45]. In these infections the prevalence of hypermutable strains is
abnormally high [46] and have been linked to antibiotic resistance
development and persistence in respiratory airways [47,48]. Thus,
one can expect that in such infections fosfomycin resistance would
develop as soon as patients begin the treatment.
As fosfomycin has been proposed as potentially useful in
combined therapy [49], we studied in vitro the probability of
acquisition of resistance to the combination of fosfomycin with
two different antibiotics, tobramycin and imipenem. While the
combination of fosfomycin with tobramycin makes improbable the
emergence of resistance to both antibiotics when administered
together, even in an hypermutable background, the results from
the combination of fosfomycin plus imipenem suggest that the
generation of mutants resistant to both antibiotics is not very
difficult for P. aeruginosa. However, additional studies are still
needed to determine the real effectiveness of fosfomycin when
administered together with these and other antibiotics. Recently
Ward et al [50] have reported that the biological cost of resistance
to a second antibiotic in P. aeruginosa could be greater than that of
previously acquired resistance. Finally, the total cost depends
on the genetic background in which resistance evolve and its
interaction with the environment. Well conducted studies are
needed to find a good combination of antibiotics where double
resistance, if available, has a sufficiently high cost to impede the
Figure 5. Histology of murine lungs after infection with P. aeruginosa. Shown are representative examples of the histology results obtained
for murine lungs 48 hours after infection with the P. aeruginosa strain PA14 (A) or PA14glpT::MAR2xT7 (B). IS, inflammatory score determined as
described by Johansen et al. [31].
doi:10.1371/journal.pone.0010193.g005
Table 3. Minimal inhibitory concentrations of the antibiotics
fosfomycin, tobramycin and imipenem for PA14 and its
derivative mutants mutS::MAR2xT7 and glpT::MAR2xT7.
Antibiotic MIC (mg/ml)
wt mutS::MAR2xT7 glpT::MAR2xT7
Fosfomycin 8 8 1024
Tobramycin 0.25 0.25 0.25
Imipenem 0.5 0.5 0.5
doi:10.1371/journal.pone.0010193.t003
Table 4. Frequency of mutants resistant to single antibiotics
and the combinations of fosfomycin with tobramycin and
imipenem.
Antibiotic Concentration
a Mutant frequency
wt mutS::MAR2xT7
Tobramycin 4 2.2610
29 1.4610
27
Imipenem 4 2.3610
26 9.1610
24
Fosfomycin 128 1.5610
26 1.1610
24
Combination
Tobramycin +Fosfomycin 4+128 ,10
211 ,10
211
Imipenem +Fosfomycin 4+128 2.1610
29 1.1610
27
a: antibiotic concentation in mg/ml.
doi:10.1371/journal.pone.0010193.t004
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We were unable to identify any condition where the inactivation
of glpT has some significant repercussion on P. aeruginosa fitness.
Biofilm formation of the defective mutant did not show any
alteration when compared with the wild type strain, which
probably indicates that this gene does not influence biofilm
development. These results are consistent with the fact that some
metabolic genes are down regulated during biofilm formation
[51,52].
In conclusion, apart from the absence of in vivo fitness cost of
fosfomycin resistance in P. aeruginosa, our findings reveal that we
need a deeper understanding of the interplay between antibiotic
resistance, biological fitness and virulence. This knowledge will be
invaluable if we aspire to improve the development of drug
antibiotherapy for the different pathogens nowadays threatening
humankind.
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